Cancer drug development in China: recent advances and future challenges  by Wu, Yi-Long et al.
R
eview
s
P
O
S
T
S
C
R
E
E
NREVIEWS Drug Discovery Today  Volume 20, Number 6  June 2015
Cancer drug development in China:
recent advances and future challenges
Yi-Long Wu1, Helena Zhang2 and Yumei Yang3
1Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou 510080, China
2Quintiles China, Shanghai 200032, China
3Quintiles China, Beijing 100006, China
Over the past 10 years, the Chinese Government, academic organizations, and biopharmaceutical
companies have tried to transition the nation from a consumer of generic drugs into a developer of
innovative therapies. Here, we present a timeline of recent innovative cancer drug development, with a
particular focus on four case studies that have reshaped perceptions of what can be done in China. We
present metrics comparing China with other countries alongside analysis of what national authorities
are doing to close the gap in areas where China still lags behind the West.Introduction
The Chinese biopharmaceutical industry is undergoing a transfor-
mation as the Government tries to move to an innovation-driven
economy by 2020. After two decades of ever-rising investment,
China now accounts for almost 18% of worldwide research and
development (R&D) spending across all industries [1]. Healthcare
is a particular priority, with the Government facing the dual
challenges of maintaining the growth of the biopharmaceutical
industry and improving the health of the population.
Widespread tobacco use, unhealthy lifestyles, and an aging
population have contributed to cancer becoming a major problem
in China. One-third of global lung cancer cases and approximately
one-half of all diagnoses of gastric, liver, and esophageal cancer
cases occur in China [2]. Improving outcomes for these patients is
a priority and work towards this goal attracted some of the US$2.7
billion the Government allocated to a special drug R&D fund from
2008 to 2010 [3].
Over the past 10 years, the number of clinical trials conducted in
China has increased substantially, with the number of early-phase
studies tripling since the 2007 Provisions of Drug Registration
promulgated in China. In addition to clinical trials conducted
for the purpose of drug registration, the number of investigator-
initiated trials (IITs) in China has doubled. To optimize
drug development and registration timelines, multinational phar-Corresponding author: Wu, Y.-L. (syylwu@live.cn)
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in China as part of their simultaneous global development (SGD)
strategies. However, industry-sponsored clinical trials (ISTs) have
increased in number only incrementally over the past 5 years
because of a lengthy new drug clinical trial authorization (CTA)
approval timeline (Fig. 1).
Since the Major New Drug Innovation Program (MNDIP) started
in 2009, approximately half of the projects funded by the initiative
have involved R&D of oncology therapies [4]. As well as investing
heavily in R&D, the Chinese Government has strengthened intel-
lectual property rights and made regulations more amenable to
innovation as it aims for the discovery of 100 innovative new drugs
by 2020. The platform for this ambitious goal has been laid over
the past two decades, but challenges remain.
To assess the health of the Chinese clinical development eco-
system as it embarks on this mission, we analyzed four sets of
innovative oncology studies that have reshaped perceptions of the
R&D capabilities of China. The first of these examined a series of
lung cancer trials that validated molecularly targeted treatment
pathways. The second detailed an early example of Chinese-led
innovation. The third and fourth case studies examined why the
unique characteristics of cancer in China make such locally driven
drug development essential.
Each case represents a milestone in the evolution of the Chinese
oncology ecosystem, with many of the same researchers and sites
featuring in each one. This continuity has enabled China to buildd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
http://dx.doi.org/10.1016/j.drudis.2014.11.005
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FIGURE 1
Trends in oncology clinical trials in China from 2004 to 2013. Data were analyzed to highlight two trends: (i) phases of clinical trials (early phase, Phase 3 and
others); and (ii) trial sponsorship, including investigator-initiated trials (IITs) and industry-sponsored trials (ISTs). Others include Phase 4 and unknown phase
studies. The figure is based upon data summarized in BioPharm Clinical, gathered from 16 international trial registries including ClinicalTrials.gov, in May 2014.
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its R&D capabilities. The Chinese Society of Clinical Oncology
(CSCO) has supported this process by working with its interna-
tional peers to prepare sponsors and investigators to develop
investigational drugs and improve multiple aspects of the research
infrastructure. Through such work, the drug developments dis-
cussed in the following case studies overcame the significant
challenges that they faced at the outset.
Oncology R&D in China: four case studies that reshaped
the sector
The following case studies have become examples of the collabo-
rative problem solving that the Government, industry, academia,
and international partners will need to perform for China to
achieve its ambitious goals. Discussions here synthesize the key
lessons gained from the cases, and how they can be applied on a
larger scale to overcome the challenges faced in China today.
Case study 1: how China moved the world towards targeted
therapies
When AstraZeneca began its IRESSA Pan-ASia Study (IPASS) in 2006,
the Chinese clinical development sector was in its infancy. That
year, IPASS was one of 200 trials registered on ClinicalTrials.gov that
planned to enroll patients at a Chinese site. Concerns about regula-
tory impartiality towards foreign drugs, the need for more align-
ment with international clinical trial standards, and the availability
of qualified staff all stymied interest in running trials in China. For
many sponsors, the risks simply outweighed the rewards.
This is no longer the case. In 2013, more than 1000 studies with
Chinese trial sites were registered on ClinicalTrials.gov and theability of the country to produce high-quality data for submission
to regulators, international journals, and health technology as-
sessment (HTA) agencies is now accepted. The success of the IPASS
trial, results from which were published in the New England Journal
of Medicine [5], is partly responsible for the shift in both percep-
tions and reality since 2006.
IPASS was an open-label, randomized, parallel-group study to
compare the efficacy of the non-small cell lung cancer (NSCLC)
drug gefitinib of AstraZeneca with carboplatin-paclitaxel chemo-
therapy as a first-line treatment. Chinese trial sites recruited
almost one third of the 1217 patients enrolled in the study and,
in doing, so hinted at the opportunities presented by the huge
population of the country. Judged on scale alone, IPASS was an
important trial for the development of the R&D ecosystem in
China.
However, the bigger impact of IPASS stems from the central role
that Chinese researchers had in developing the complex trial and
the far-reaching global implications of the data that it generated.
The discovery that patients with NSCLC and with epidermal
growth factor receptor (EGFR) mutations responded better to
gefitinib compared with the general population began the shift
towards molecularly targeted treatment pathways for lung cancer.
Subsequent Chinese trials had a key role in accelerating this
transition.
In the wake of IPASS, F. Hoffmann-La Roche turned to Chinese
sites to study the effect of its therapy in patients with activating
EGFR mutations. Tony Mok, Yi-Long Wu, and other veterans of
the IPASS trial were enlisted to work on FASTACT-2, which con-
firmed many of the lessons learned in the earlier study. Median
overall survival (OS) in patients with the EGFR mutation was 31.4www.drugdiscoverytoday.com 767
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The data were published in The Lancet Oncology in 2013 [6].
The findings of AstraZeneca and Roche added to data generated
by a collaborative clinical research group, the Chinese Thoracic
Oncology Group (CTONG) [7]. In 2011 [8] and 2012 [9], CTONG
papers published in The Lancet Oncology described its OPTIMAL
and INFORM Phase 3 trials, both of which focused on the targeted
therapy field. Collectively, IPASS, FASTACT-2, OPTIMAL, and
INFORM reshaped treatment modalities and the lung cancer drug
development paradigm by showing the value of targeted therapies.
The series of internationally acclaimed NSCLC studies also dem-
onstrated what Chinese trial sites were capable of attracting top
global companies. Amgen, Eli Lilly, Sanofi, and Pfizer have each
worked with clinical trial sites that participated in FASTACT-2.
Case study 2: an early success for Chinese innovation.
Whereas the NSCLC studies put Chinese trial sites on the map
internationally, in isolation they did little to counter the continu-
ing perception that local companies are better at following than
innovating. The trials were codeveloped and conducted by Chi-
nese researchers, but the drugs that they tested emerged from the
laboratories of overseas companies. Icotinib was different. Here
was an example of an EGFR tyrosine-kinase inhibitor (TKI) devel-
oped in China [10].
In 2005, Zhejiang Beta Pharma advanced icotinib into clinical
development. After five Phase 1, two Phase 1/2 and one Phase 3 trials
conducted within 5 years [11–14], it became the third company to
win approval for an EGFR TKI in China. The clinical program is
evidence of how China not only has learned from global firms, but
also has the skill and knowledge to move beyond their templates.
Icotinib has the same mechanism of action as gefitinib and erlotinib
and is viewed as a ‘me-too’ drug, but Zhejiang Beta Pharma decided
not to copy the R&D models of Roche and AstraZeneca because of
the changing development environment.
Instead, Zhejiang Beta Pharma designed its own double-blind,
randomized controlled trials that brought icotinib to market faster
and at lower cost than is typical in the West, but still adhering to
global quality and ethical standards. Regular communications
with the Center for Drug Evaluation (CDE) helped foresee and
prevent delays, showing both local and global companies how to
streamline development timelines in China. Icotinib went from
early-phase development to launch in just 8 years [15]. Zhejiang
Beta Pharma has passed the savings on to the healthcare system,
giving Chinese patients a drug with better tolerability and similar
effectiveness compared with gefitinib at a lower cost. Although the
studies had flaws, such as incomplete OS data and the decision not
to use biomarkers, they still added to knowledge of NSCLC,
particularly the fact that only certain patients benefit from tar-
geted maintenance therapy or second-line targeted treatment.
Case study 3: Chinese-specific tumor types
The unique characteristics of the Chinese population are one
factor that attracted trials to China, with the higher prevalence
of EGFR mutations pulling in NSCLC studies. However, the ethnic
differences between China and the West also cause problems.
China is disproportionately affected by hepatocellular carcinoma
(HCC), with more than half of global new cases occurring in the
country [2]. Additionally, the prognosis is poorer. Given best768 www.drugdiscoverytoday.comsupportive care (BSC), the average Westerner will live 6–9 months:
the average survival in China is half that [16].
For drug developers, the differences that underpin these survival
expectations are problematic. HCC in China, which is a clearly
unmet medical need, is primarily caused by hepatitis B, whereas in
the West, hepatitis C and alcoholic cirrhosis are the main drivers.
When hepatitis B is the cause, HCC has different oncogenic driver
mutations, protein functions, and intracellular signaling path-
ways. When developing a targeted drug, this effectively makes
HCC in China a different disease than in the West. In the EACH
study, Chinese researchers tried to meet this need by designing
and running a trial with sites in China, Korea, Thailand, and
Taiwan. Chinese sites recruited 70% of the 370 patients, each of
whom was given either doxorubicin or an infusion of fluorouracil,
leucovorin, and oxaliplatin, known as FOLFOX4. When data were
first presented at the American Society of Clinical Oncology
(ASCO) meeting in 2010, they demonstrated the validity of a
systemic chemotherapy regimen with lighter toxicity [17].
FOLFOX4 increased OS by 1.47 months, a significant change for
a population in which individuals are only expected to live up for
to 4 months. Progression-free survival (PFS) and response rate also
improved. Although the trial missed its primary endpoint, the
positive trends of clinical advantage and significant unmet need
meant that it nonetheless showed that the therapy is an effective
choice, and it was approved by the China Food and Drug Admin-
istration (CFDA). The treatment is well suited to patients with
milder symptoms, or those with poorer economic conditions.
Case study 4: anticancer drug originates in China
The disease heterogeneity that defines HCC is also seen in gastric
cancer, with different epidemiology, etiology, tumor location,
pathological biology, clinical manifestations, and disease manage-
ment in China compared with the West. Again, China accounts for
around half of global new cases occurring every year, and the
combination of later diagnosis, lower removal rate, and higher
incidence of metastases makes this disease particularly devastat-
ing. In China, the 5-year survival rate is less than 50% [18] and,
therefore, the unmet need is enormous.
With gastric cancer in China being associated with a unique mix
of causes and outcomes, a treatment developed for overseas mar-
kets can be unsuccessful in this country. There is a need for drugs
developed in China, for Chinese patients. The evidence is so clear
that Jiangsu Hengrui Medicine Co. is currently working to meet
this need. Its clinical gastric cancer candidate, the vascular endo-
thelial growth factor receptor (VEGFR) inhibitor apatinib, is being
developed by Chinese researchers for Chinese patients.
Data from a Phase 2 trial of apatinib, which recruited 144
patients at 22 sites across China, was published in the Journal of
Clinical Oncology in 2013 [19]. Having demonstrated that apatinib
was associated with statistically significant increases in OS and PFS
and had tolerable toxicities, Jiangsu Hengrui Medicine Co. ad-
vanced the drug into Phase 3 development. In total, 273 patients
were recruited at 37 Chinese sites and, again, statistically and
clinically significant survival benefits were seen [20].
Apatinib is now waiting for new drug application (NDA) approv-
al. The decision would have significant implications for patients
and the treatment of gastric cancer. Jiangsu Hengrui Medicine tested
apatinib in heavily pretreated patients with metastatic gastric
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more lines of chemotherapy regimens. In clinical trials, apatinib was
shown to improve health outcomes for these difficult-to-treat
patients, suggesting that its antiangiogenic approach has potential.
For China, the successful completion of a Phase 3 trial of an
innovative drug by an independent local company represents the
culmination of the decade of work as discussed in the case studies
presented previously. The clinical trial sites of the country have
gone from being on the fringes of global development to working
with local companies and multinational giants to design and run
first-time studies using innovative medicines. What comes next
depends on the optimization of overall drug development capa-
bilities, but such optimization will facilitate continuation of their
upward trajectory.
The next steps: four areas in which China must improve
The case studies presented above demonstrate how far China has
come in just 10 years. However, there are still areas in which the
drug development capability of the country can improve. Here,
four problem areas for China are examined: (i) early-phase devel-
opment and regulatory oversight; (ii) pharmacogenomic and bio-
marker-driven studies; (iii) site network building; and (iv) data0
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The number of filings and approvals for antitumor new drug clinical trial authoriza
Administration (CFDA) from 2007 to 2013 is compared for domestic and imported 
entities into six categories. Categories 1–4 are defined as ‘new drugs’ and categorie
categories, category 1 and 3, are also analyzed and presented in this figure. The gra
(CPM), China National Pharmaceutical Industry Information Center in May 2014. Ca
approval for a new route of administration not yet approved in any country; Catego
drugs made by changing the acidic or alkaline radicals or metallic elements of the sa
effects. In addition, CFDA designates previously approved therapies outside China a
support an IDL application.quality. Each is a potential constraint on the growth of Chinese
cancer drug development, but initiatives are already in place to
drive improvements.
Step 1: early-phase development and regulatory oversight
Although several Chinese companies are dedicated to innovative
drug development, overall capabilities are still weak because of the
lack of overall clinical development strategy. Limited awareness of
risk and complexity is a particular bottleneck to innovative drug
development [21]. Investigators must also gain experience of early-
phase development if China is to truly participate in SGD pro-
grams from the earliest stages of clinical development. Although
the number of early-phase trials in China has tripled in recent
years, the decision of the CDE to prioritize the strengthening of the
field will lead to further gains.
The strategy of the CDE of encouraging drug innovation and
allocating resources to reviewing trial applications, despite human
resource constraints at CFDA, has already begun to pay dividends
[22]. New drug CTA filings have increased fourfold since
2007, among which domestic innovative drug (Category 1 and
2) submissions have tripled (Fig. 2). However, the goal is to make
further enhancements. For example, average review timeline is010 20 11 2012 2013 
ear 
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approvals. In China, companies also have to wait longer for the
regulatory approval compared with companies in other countries
[23]. The difference leaves only a small time window for patient
recruitment, possibly cutting the likelihood of China being in-
cluded in global early-phase clinical trials.
First-in-human (FIH) trials must also use a drug that is manu-
factured in China by a domestic company or a local affiliate of an
international company. Consequently, a FIH global trial cannot be
approved in China if the compound was developed in another
country. The upshot is that patients must wait to access potentially
life-saving oncology treatments.
IITs are another area of interest for regulators. The trickle down
of knowledge from pharmaceutical companies to Chinese sites has
led to more local investigators developing the expertise and expe-
rience, along with funding (in the form of grants from industry,
government or universities), to initiate trials. Over the past decade,
the number of IITs has soared (Fig. 1), and these studies have an
important role.
In China, oncology drugs are used widely outside of approved
labeling, but such prescribing decisions can lack evidence-based
justifications. IITs help to standardize the unlabeled use of med-
icines by providing evidence, a necessary activity given the need
for regulations covering the topic; however, this can also lead to
serious adverse events (SAEs) and other risks. Regulatory guidance
for IITs is needed to ensure that the benefits outweigh the risks.
Overall, the clinical trial environment in China has improved
over the past 5 years as the result of significant efforts on the part of
the Government. CFDA is actively reforming the regulatory frame-
work for conducting clinical trials and is likely to further adjust its
policies in step with advances in early-phase research and over-
sight of IITs.
Step 2: applications of pharmacogenomic and biomarker-driven
studies
With the increasing awareness of the Chinese Government of
human genetic resources coverage, intellectual property rights,
and national security in R&D activities, the Human Genetic Re-
source Administration of China (HGRAC) has tended to tighten
the requirements of genomic samples and electronic data export.
Moreover, licensed institutions in China are the only entities that
can legally collect, store, and provide human genetic resources.
Drug metabolism cytochrome P-450 single nucleotide polymor-
phism (SNP) genetic assays for personalized medicine are gradually
being developed in the laboratories of Chinese hospitals, but
pharmacogenomics clinical research in China is still in an early
stage, lacking sufficient scientific data to validate their use within a
clinical setting [24]. Although some recent genome-wide associa-
tion studies show prognostic and potential targeted therapeutic
implications in Chinese esophageal or laryngeal squamous cancers
[25–27], most studies face challenges in immature testing meth-
odologies, inadequate sample size, poor repeatability of results
among sites, and ethical concerns.
IPASS and the other EGFR trials also showed why biomarker-
driven drug development is needed in China, but aspects of the
infrastructure of the country are limiting uptake. An insufficient
number of qualified laboratories are slowing genotyping requests:
for example, EGFR testing rates are 10% [28]. China made EGFR770 www.drugdiscoverytoday.comtesting part of its guidelines and encouraged hospitals to add
capacity. CFDA approved the first next-generation sequencing
diagnostic products in 2014. In addition, multiple efforts from
the Chinese Government are underway, including funding sup-
ports and applied technology innovation service platforms for
pharmacogenomics that are proposed to help local pharmaceuti-
cal companies during the drug discovery process. Furthermore,
increasing numbers of global trials conducted in China have
optional pharmacogenomics assessments. Interestingly, patients
with NSCLC in a current Phase 2 study will be allocated a specific
treatment arm based on their primary genetic profiling analysis,
and it remains open to add new candidate compounds with
targetable genetic alterations. The innovative design of the cluster
trials suggests a profound impact on future cancer R&D in China
[29].
In these areas, CDE can learn from its regulatory peers in the
USA and Europe. Events such as the Advanced Clinical Trial
Workshop China (ACT China), which is run by CSCO and the
Society for Translational Oncology (STO), provide a platform for
the spread of regulatory ideas and practices by bringing represen-
tatives from the CFDA, US Food and Drug Administration (FDA),
and the European Medicines Agency (EMA) together. At ACT
China 2013, CFDA, FDA, and EMA discussed the way forward
for biomarker-driven targeted drug development in China. CSCO
also has a biomarker committee and exchanges ideas with its
global peers.
Step 3: clinical trial site network building
China can clear another bottleneck by learning site network-
building skills from such exchanges. CFDA has accredited 173
good clinical practice (GCP) oncology trial sites, but there is room
for growth. In the USA, the National Cancer Institute’s Clinical
Trials Cooperative Group Program includes 3100 institutions and
14,000 investigators. Given the population of China, the country
could become the global engine of cancer research and improving
outcomes for its people in the process.
The China Thoracic Oncology Group (CTONG) behind the OP-
TIMAL and INFORM trials, is working to realize this ambition. The
organization, which now comprises 23 sites, was founded in 2007 to
bring together researchers, physicians, and healthcare professionals
at public institutions across China. Together, the collaborators work
to design multicenter clinical trials, promote standardization, mod-
ernization, and internationalization, improve treatment and diag-
nosis, and provide evidence for therapies.
Currently, the network was running over 20 trials and had
approximately 20,000 patients with lung cancer in its database;
however, it is still in its infancy. If China is to improve cancer
outcomes for not only its population, but also patients around the
world, trials such as the OPTIMAL study that helped erlotinib
become registered for first-line therapy must become common-
place. In this era of personalized medicine, China can develop
more collaborative clinical trial groups and solve the problems
facing its existing organizations.
Step 4: data quality
The issue of data quality has become a rate-limiting factor in drug
development and is seriously affecting the objective evaluation
of drug efficacy and safety, negatively impacting the R&D of
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market. Regulating data management and ensuring the authen-
ticity and integrity of data is vital to the future of Chinese oncolo-
gy drug development. Educational efforts should focus on
equipping clinical trial investigators to closely follow GCP prin-
ciples, and meticulously record their activities in a timely manner.
The long duration and complexity of cancer trials make the timely
resolution of data queries both particularly important and challeng-
ing. Experienced Contract Research Organization (CRO) partners
who proactively communicate to resolve issues on time would be
essential. Patients with advanced cancer often have shorter survival
and higher drop-out rates because of the relatively high frequency of
serious SAEs caused by antitumor drugs. The reliance on PFS, ORR,
and time to tumor progression as endpoints makes evaluations
susceptible to interference by subjective judgment. Independent
clinical event committees (CECs) and data monitoring committee
(DMCs) must be expanded to mitigate this risk in China.
Concluding remarks
Although the four next steps discussed above represent signifi-
cant challenges for China, they look manageable, especiallywhen considered in light of how much Chinese drug develop-
ment capabilities have improved over the past decade. With the
significant support of the goverment and through CFDA’s
reforms of the regulatory framework, China has become a favor-
able location for drug development. By continuing to refine
its policies, CFDA can help China fulfill its potential in this
field.
Other stakeholders will also have important roles. The case
studies show the value of collaboration among regulators, acade-
mia, and industry. If China is to replicate, and expand upon, the
successes of the past decade in the coming years, it must continue
along this path, with local players learning from each other and
their global peers. Projects such as CSCO’s Oncology Drug Clinical
Development and Safety Evaluation Committee (a collaborative
platform for academia, regulators, and industry) provide an exam-
ple of such learning.
If China can address the four constraints discussed, and work
through Government, academic organizations, and biopharma-
ceutical companies suggests that it can, the country will have laid
the groundwork for cancer drug development that will improve
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